
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is a promising healthcare company with strong potential for growth due to its innovative, multi-cancer early detection blood test that has the ability to detect all types of cancer, providing a significant advantage over its competitors. The company has shown strong performance in their first quarter results, with revenue beating expectations and volume growing by 50% year-over-year. Despite the challenges and uncertainties of FDA approval and reimbursement, GRAIL has established a significant market presence, and is primed for broader institutional adoption and continued success in the rapidly growing multi-cancer early detection market.
Bears say
GRAIL is facing uncertainties and variability in their 22%-23% revenue growth guide due to factors such as uncertainty in digital health partner uptake and post-ASCO ordering trends, the newer and unproven nature of Hims & Hers and WHOOP, and variability from the sales force ramp. Additionally, there are risks to the medical and life science tools sector that could negatively impact GRAIL, such as reduction in research and development budgets and government funding, decreased purchasing from healthcare customers, increased regulatory hurdles, and dependence on volatile emerging markets. Overall, these factors could potentially hinder GRAIL's growth and profitability.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares